Management of Molar Pregnancy and Post‑Molar Gestational Trophoblastic Neoplasia (RCOG‑aligned)
Initial Evacuation
- Women with a confirmed molar pregnancy should be treated with ultrasound‑guided suction dilation and curettage (D&C) as the primary method, irrespective of uterine size, when fertility preservation is desired. (RCOG recommendation) 1
- Suction D&C is the safest evacuation technique, providing complete removal of molar tissue while minimizing uterine perforation risk. (RCOG recommendation) 1
- Rh‑negative patients must receive Rho(D) immunoglobulin at the time of evacuation to prevent allo‑immunisation. (RCOG recommendation) 2
Role of a Second Curettage
- A repeat D&C for persistent disease does not reliably avoid the need for chemotherapy and carries a significant risk of uterine perforation. (RCOG recommendation) 1
- Any consideration of re‑evacuation should be made only after discussion with a specialised gestational trophoblastic disease (GTD) reference centre. (RCOG recommendation) 1
Post‑Evacuation hCG Surveillance
- All patients require serial quantitative serum hCG monitoring performed in the same laboratory with the same assay throughout follow‑up to detect post‑molar GTN. (RCOG recommendation) 3
- Serum hCG should be measured every 1–2 weeks until three consecutive normal values (< 5 mIU/mL) are obtained. (RCOG recommendation) 3
- If hCG normalises after 56 days post‑evacuation, monthly measurements must continue for a total of six months. (RCOG recommendation) 3
- For complete (diploid) hydatidiform mole, an extended six‑month monthly surveillance after hCG normalisation is advised. (RCOG recommendation) 3
Indications for Chemotherapy (Post‑Molar GTN Criteria – FIGO/UK)
- Chemotherapy is indicated when any FIGO/UK criteria are met after evacuation. (RCOG recommendation) 3
Primary hCG‑based criteria
- Plateaued hCG: ≥ 4 equivalent values over ≥ 3 weeks (days 1, 7, 14, 21). (RCOG recommendation) 3
- Rising hCG: Two consecutive increases ≥ 10 % over ≥ 2 weeks (days 1, 7, 14). (RCOG recommendation) 3
- Persistent hCG: Detectable hCG ≥ 6 months after evacuation (note: this criterion has been omitted in recent UK guidance). (RCOG recommendation) 2
- Elevated hCG: Serum hCG ≥ 20 000 IU/L more than 4 weeks post‑evacuation (associated with higher uterine perforation risk). (RCOG recommendation) 3
Additional clinical criteria
- Heavy vaginal bleeding requiring transfusion, even if hCG is falling. (RCOG recommendation) 3
- Histological confirmation of choriocarcinoma on tissue diagnosis. (RCOG recommendation) 3
- Documented metastases to brain, liver, or gastrointestinal tract. (RCOG recommendation) 3
- Lung opacities > 2 cm on chest X‑ray (smaller lesions may regress spontaneously). (RCOG recommendation) 2
Staging and Risk Stratification
- Initial work‑up of post‑molar GTN includes pelvic Doppler ultrasound (to exclude new pregnancy, assess uterine size, pelvic spread, and vascularity via pulsatility index—an independent predictor of methotrexate resistance). (RCOG recommendation) 3
- A chest X‑ray is mandatory as the lungs are the most common metastatic site. (RCOG recommendation) 3
- If chest X‑ray shows lesions > 1 cm, immediate MRI of the brain and CT of chest/abdomen are required to rule out brain or liver metastases, which markedly change treatment strategy. (RCOG recommendation) 3
With a normal chest X‑ray, further imaging is unnecessary; CT‑detected micrometastases (~40 % of cases) do not affect outcome or management in low‑risk disease. (RCOG recommendation) 3
- The FIGO 2000 prognostic scoring system should be used to guide treatment intensity and predicts resistance to single‑agent chemotherapy. (RCOG recommendation) 3
- Low‑risk (FIGO score 0–6): single‑agent chemotherapy. (RCOG recommendation) 3
- High‑risk (FIGO score ≥ 7): multi‑agent combination chemotherapy. (RCOG recommendation) 3
- The FIGO score is not applicable to placental‑site trophoblastic tumour (PSTT) or epithelioid trophoblastic tumour (ETT). (RCOG recommendation) 4
Treatment Regimens
Low‑Risk Disease (FIGO 0–6)
- Methotrexate with folinic acid (MTX/FA) is the preferred first‑line regimen in most European centres because it is less toxic than methotrexate alone or actinomycin D, and cure is expected even if first‑line fails. (RCOG recommendation) 4
- Single‑agent actinomycin D is an acceptable alternative. (RCOG recommendation) 4
- Chemotherapy should be continued for 6 weeks of maintenance after hCG normalisation. (RCOG recommendation) 4
High‑Risk Disease (FIGO ≥ 7)
- EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) is the standard multi‑agent regimen; it is highly effective, simple to administer, and relatively non‑toxic. (RCOG recommendation) 4
- Maintenance therapy continues for 6 weeks after hCG normalisation, extended to 8 weeks in patients with poor prognostic features such as liver ± brain metastases. (RCOG recommendation) 4
- For ultrahigh‑risk patients, induction with low‑dose etoposide + cisplatin (EP) before EMA/CO reduces early mortality. (RCOG recommendation) 4
- Substituting EMA/CO with EP/EMA may be advantageous in selected ultrahigh‑risk cases. (RCOG recommendation) 4
Salvage Therapy for Treatment Failure
- High‑risk failures can often be salvaged with EP/EMA or TE/TP regimens. (RCOG recommendation) 4
- Isolated chemoresistant disease may be managed surgically, achieving cure in selected patients. (RCOG recommendation) 4
- Residual lung or uterine masses after chemotherapy do not predict recurrence and do not require surgical excision. (RCOG recommendation) 4
Special Tumour Types (PSTT / ETT)
- Stage I disease presenting ≤ 4 years after the last pregnancy: hysterectomy with pelvic lymph‑node sampling. (RCOG recommendation) 4
- Metastatic disease: multi‑agent chemotherapy (e.g., EP/EMA). (RCOG recommendation) 4
- Presentation > 4 years after the last pregnancy: consider multi‑agent chemotherapy followed by high‑dose regimens. (RCOG recommendation) 4
Centralisation of Care
- Management of GTN is optimised by centralising care, pathology review, and hCG monitoring at specialised GTD reference centres. (RCOG recommendation) 4
- Centralised care improves outcomes through standardised protocols, expert pathology review, and coordinated surveillance. (RCOG recommendation) 4
- All treatment decisions for persistent GTN should involve consultation with a GTD reference centre. (RCOG recommendation) 1
Management of Molar Pregnancy
Initial Diagnosis and Assessment
- The National Comprehensive Cancer Network recommends that molar pregnancy is often diagnosed based on ultrasound findings, clinical symptoms, and elevated hCG levels 5
- Characteristic ultrasound findings for complete molar pregnancy include a heterogeneous mass ("snowstorm" appearance), absence of fetal development, and possible theca-lutein ovarian cysts 6
- Characteristic ultrasound findings for partial molar pregnancy include focal cystic spaces within placenta, abnormal gestational sac, and possible fetal anomalies 5
- A complete workup should include history and physical examination 7, quantitative hCG assay 6, complete blood count with platelets 5, liver, renal, and thyroid function tests 5, blood type and screen 5, and chest X-ray 5
Primary Management
- The American College of Obstetricians and Gynecologists and the National Comprehensive Cancer Network recommend surgical evacuation by suction dilation and curettage (D&C) under ultrasound guidance as the treatment of choice for molar pregnancy in women who wish to preserve fertility 6, 5
- Suction D&C under ultrasound guidance is the safest method to ensure adequate emptying of uterine contents and avoid uterine perforation 6
- Administer Rho(D) immunoglobulin at evacuation to patients with Rh-negative blood types 5
- Uterotonic agents (e.g., methylergonovine, prostaglandins) should be used during and after the procedure to reduce risk of heavy bleeding 5
Post-Evacuation Monitoring
- The National Comprehensive Cancer Network recommends that all women with molar pregnancy require careful hCG monitoring to detect potential development of gestational trophoblastic neoplasia (GTN) 6
- hCG monitoring should be done every 1-2 weeks until levels normalize (defined as 3 consecutive normal assays) 7
- After normalization, hCG should be measured twice in 3-month intervals 5
- Reliable contraception should be used during the entire follow-up period 5
Criteria for Post-Molar GTN
- Post-molar GTN is diagnosed when meeting any of the following FIGO criteria: hCG levels plateau for 4 consecutive values over 3 weeks 8, hCG levels rise >10% for 3 values over 2 weeks 9, or hCG persistence 6 months or more after molar evacuation 5, 8
Management of Post-Molar GTN
- If GTN is diagnosed, additional staging workup includes Doppler pelvic ultrasound 7 and chest X-ray (if positive, proceed with MRI brain and CT body) 8, 10
- Treatment is based on FIGO scoring system that predicts resistance to single-agent chemotherapy: low-risk (score 0-6) is treated with single-agent chemotherapy (methotrexate or actinomycin D) 10, and high-risk (score ≥7) is treated with multi-agent chemotherapy 9
- Indications for chemotherapy include plateaued or rising hCG after evacuation 8, heavy vaginal bleeding 8, histological evidence of choriocarcinoma 6, evidence of metastases 8, and serum hCG ≥20,000 IU/L >4 weeks after evacuation 8
Special Considerations
- Re-biopsy to confirm malignant change is not advised due to risk of triggering life-threatening hemorrhage 6
- Prophylactic chemotherapy at time of evacuation is controversial and generally not recommended as standard practice, but may be considered for high-risk patients 5
- Risk factors for post-molar GTN include age >40 years 7, hCG levels >100,000 mIU/mL 8, excessive uterine enlargement 5, and theca lutein cysts >6 cm 5, 7
Evidence‑Based Recommendations for Management of 16‑Week Molar Pregnancy
Diagnostic Confirmation
- Histological examination of all evacuated uterine tissue is required to establish a definitive diagnosis of molar pregnancy, even when ultrasound demonstrates the classic “snowstorm” appearance. 11
Post‑Evacuation hCG Surveillance
- Serial quantitative serum β‑hCG measurements must be performed using the same laboratory and assay for the entire monitoring period to avoid inter‑assay variability that could mislead clinical decisions. 11
- If serum β‑hCG results are inconsistent with the clinical picture, the test should be repeated with an alternative assay and corroborated with a urine β‑hCG measurement to exclude false‑positive serum values. 11
Long‑Term Reproductive Outlook
- After successful treatment of a molar pregnancy, the risk of a recurrent molar pregnancy in subsequent conceptions is approximately 1 %. 11